Murjne Anti‐Idiotypic Monoclonal Antibodies to Syngeneic Antihuman High Molecular Weight‐Melanoma Associated Antigen Monoclonal Antibodies: Development, Characterization, and Clinical Applications

Abstract

Following a discussion of the rationale underlying the selection of human melanoma to test the usefulness of anti‐idiotypic monoclonal antibodies in the therapy of solid tumors, the development of the anti‐idiotypic monoclonal antibody MoAb) MF11–30 is described. This antibody recognizes a private idiotope within the antigen‐combining site of the immunizing antihuman high molecular weight melanoma‐associated antigen MoAb 225.28. The results of a phase I clinical trial with the MoAb MF11–30 in patients with advanced melanoma are described. The lack of toxic effects and the minor responses in six patients suggest that these studies should be extended to a larger number of patients with an emphasis on the analysis of the mechanisms underlying the clinical response.